Abstract: The present invention relates to the field of unmanned aerial vehicle safety protection technologies, and in particular, to an unmanned aerial vehicle safety protection method and apparatus and an unmanned aerial vehicle. The method includes: obtaining ultrasonic information and a flight status of an unmanned aerial vehicle, where the flight status includes a normal flight state and a descending state; and performing safety protection on the unmanned aerial vehicle according to the ultrasonic information and the flight status. The implementation can reduce an occurrence probability that an unmanned aerial vehicle crashes at a high altitude when ultrasound encounters abnormalities to get out of control at the high altitude and fail to descend, rise, move to the left or move to the right and land without slowing down to violently hit the ground, so that the safety of the unmanned aerial vehicle is enhanced, and user experience is improved.

Abstract: The present invention discloses an unmanned aerial vehicle and a method for controlling a gimbal thereof. The method for controlling a gimbal includes: generating, by a flight control system, a yaw angular speed instruction of the unmanned aerial vehicle; and controlling, by a gimbal control system, a yaw axis motor of the gimbal according to the yaw angular speed instruction of the unmanned aerial vehicle. In the present invention, the yaw axis motor of the gimbal is jointly controlled by the flight control system and the gimbal control system, so that advantages of high-precision control and quick response of the gimbal control system are maximized. The advantages are used for compensating for deficiencies of the flight control system in yaw control, thereby improving the stability of a yaw channel of the gimbal, and completely resolving frame freezing of an aerial video when the unmanned aerial vehicle yaws at a low speed.

Abstract: Embodiments of the present disclosure provide a thermoelectric laser power probe, including a heat dissipation housing and a laser power probing unit fixed inside the heat dissipation housing. The heat dissipation housing is provided with a light inlet. The laser power probing unit includes a substrate. The substrate includes a top surface and at least two outer side surfaces. The top surface is provided with an absorbent material layer. The absorbent material layer corresponds to the light inlet. The at least two outer side surfaces are symmetrically arranged about a center line of a cross section of the top surface, each of the outer side surfaces is perpendicular to the top surface or a tangent plane of the top surface, and each of the outer side surfaces is sequentially provided with an insulating layer and a thin-film thermopile.

Abstract: Described is an N-terminal hexapeptide fragment of maximakinin, QUB 698.8, which exhibits potent tissue selective actions on smooth muscle. It demonstrates a high degree of selectivity for arterial smooth muscle over small intestinal smooth muscle, causing potent relaxation of arterial smooth muscle, while causing less potent contraction of ileal smooth muscle. It may be used treatment of diseases of the cardiovascular system and in promotion of angiogenesis.

Abstract: Described is an N-terminal hexapeptide fragment of maximakinin, QUB 698.8, which exhibits potent tissue selective actions on smooth muscle. It demonstrates a high degree of selectivity for arterial smooth muscle over small intestinal smooth muscle, causing potent relaxation of arterial smooth muscle, while causing less potent contraction of ileal smooth muscle. It may be used treatment of diseases of the cardiovascular system and in promotion of angiogenesis.

Abstract: Described is an N-terminal hexapeptide fragment of maximakinin, QUB 698.8, which exhibits potent tissue selective actions on smooth muscle. It demonstrates a high degree of selectivity for arterial smooth muscle over small intestinal smooth muscle, causing potent relaxation of arterial smooth muscle, while causing less potent contraction of ileal smooth muscle. It may be used treatment of diseases of the cardiovascular system and in promotion of angiogenesis.

Abstract: A bradykinin B2-receptor antagonist peptide, kinestatin, isolated from toad (Bombina maxima) defensive skin secretion, and analogs thereof, is disclosed. The structure of kinestatin is pGlu-Leu/Ile-Pro-Gly-Leu/Ile-Gly-Pro-Leu/Ile-Arg-NH2. Also disclosed are kinestatin analogs, prodrugs including the peptides, fusion peptides and multimeric peptides including the peptide sequences, pharmaceutical compositions including kinestatin and analogs thereof, prodrugs, fusion and multimeric peptides thereof, nucleic acids encoding kinestatin and analogs thereof, and nucleic acids encoding the fusion and multimeric peptides. Kinestatin and analogs thereof (including the prodrugs and multimeric and/or fusion peptides) can be used to treat and/or prevent disorders associated with bradykinin, including cardiovascular disorders, inflammation, asthma, allergic rhinitis, pain, angiogenesis and the like.

Abstract: Described is an N-terminal hexapeptide fragment of maximakinin, QUB 698.8, which exhibits potent tissue selective actions on smooth muscle. It demonstrates a high degree of selectivity for arterial smooth muscle over small intestinal smooth muscle, causing potent relaxation of arterial smooth muscle, while causing less potent contraction of ileal smooth muscle. It may be used treatment of diseases of the cardiovascular system and in promotion of angiogenesis.

Abstract: A bradykinin B2-receptor antagonist peptide, kinestatin, isolated from toad (Bombina maxima) defensive skin secretion, and analogs thereof, is disclosed. The structure of kinestatin is pGlu-Leu/Ile-Pro-Gly-Leu/Ile-Gly-Pro-Leu/Ile-Arg-NH2. Also disclosed are kinestatin analogs, prodrugs including the peptides, fusion peptides and multimeric peptides including the peptide sequences, pharmaceutical compositions including kinestatin and analogs thereof, prodrugs, fusion and multimeric peptides thereof, nucleic acids encoding kinestatin and analogs thereof, and nucleic acids encoding the fusion and multimeric peptides. Kinestatin and analogs thereof (including the prodrugs and multimeric and/or fusion peptides) can be used to treat and/or prevent disorders associated with bradykinin, including cardiovascular disorders, inflammation, asthma, allergic rhinitis, pain, angiogenesis and the like.